Target Name: ZNF213
NCBI ID: G7760
Review Report on ZNF213 Target / Biomarker Content of Review Report on ZNF213 Target / Biomarker
ZNF213
Other Name(s): Zinc finger protein with KRAB and SCAN domains 21 | ZKSCAN21 | zinc finger protein with KRAB and SCAN domains 21 | zinc finger protein 213 | CR53 | putative transcription factor CR53 | Putative transcription factor CR53 | ZN213_HUMAN | ZSCAN53 | Zinc finger protein 213 | Zinc finger protein 213, transcript variant 1 | ZNF213 variant 1

ZNF213: A Potential Drug Target and Biomarker

Zinc finger proteins (ZFPs) are a family of transmembrane proteins that play a crucial role in various cellular processes. ZNF213, a protein encoded by the ZNF2 gene, is a ZFP that is expressed in various tissues and is known to function in the regulation of cell proliferation, differentiation, and survival. In recent years, the study of ZNF213 has gained significant interest due to its potential as a drug target and biomarker.

The ZNF213 protein is composed of a zinc finger domain, a KRAB domain, and a SCAN domain. The zinc finger domain is a conserved region that is characterized by a specific pattern of amino acid residues. The KRAB domain is a protein kinase-associated domain that is known to play a role in cell signaling pathways. The SCAN domain is a short protein-coding region that is involved in the formation of a protein-protein interaction complex.

ZNF213 is a key regulator of cell proliferation and has been shown to play a role in the regulation of various cellular processes, including cell cycle progression, apoptosis, and angiogenesis. ZNF213 has been shown to be involved in the regulation of cell growth, differentiation, and survival, as well as in the regulation of cell-cell and cell-tumor interactions.

One of the key functions of ZNF213 is its role in the regulation of the cell cycle. ZNF213 has been shown to play a role in the regulation of G1 phase, S phase, and G2 phase of the cell cycle, as well as in the regulation of the cytoskeleton. These functions are important for the proper functioning of the cell and are critical for the regulation of cell proliferation and growth.

In addition to its role in cell cycle regulation, ZNF213 has also been shown to be involved in the regulation of apoptosis. ZNF213 has been shown to play a role in the regulation of cell apoptosis, as well as in the determination of the timing of apoptosis. These functions are important for the regulation of cell life and death and are critical for the maintenance of tissue homeostasis.

ZNF213 has also been shown to be involved in the regulation of angiogenesis. Angiogenesis is the process by which new blood vessels are formed, and this process is critical for the development and maintenance of tissues. ZNF213 has been shown to play a role in the regulation of angiogenesis, as well as in the regulation of vascular permeability. These functions are important for the proper functioning of the circulatory system and are critical for the regulation of blood flow.

In conclusion, ZNF213 is a protein that is involved in a variety of cellular processes, including cell cycle regulation, apoptosis, and angiogenesis. These functions are important for the proper functioning of cells and are critical for the regulation of tissue homeostasis. As a result, ZNF213 is a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of ZNF213 in cellular processes and to develop effective treatments for these diseases.

Protein Name: Zinc Finger Protein 213

Functions: May be involved in transcriptional regulation

The "ZNF213 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF213 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304 | ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34